Publications:

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.

Cell Death & Disease

Das, Ishani I; Wilhelm, Margareta M; Höiom, Veronica V; Franco Marquez, Rodolfo R; Costa Svedman, Fernanda F; Hansson, Johan J; Tuominen, Rainer R; Egyhàzi Brage, Suzanne S

Publication Date: 2019-09-10

Variant appearance in text: ERBB2: 181G>T; Glu61*

PubMed Link: 31506424

Variant Present in the following documents:

• 41419_2019_1875_MOESM2_ESM.pdf

View BVdb publication page

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma.

Ebiomedicine

O'Donnell, Elizabeth E; Mahindra, Anuj A; Yee, Andrew J AJ; Nardi, Valentina V; Birrer, Nicole N; Horick, Nora N; Borger, Darrell D; Finkelstein, Dianne D; Iafrate, John A JA; Raje, Noopur N

Publication Date: 2015-01

Variant appearance in text: ERBB2: Glu61X

PubMed Link: 26137536

Variant Present in the following documents:

• mmc1.pdf

View BVdb publication page

Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.

Plos One

Sherwood, James L JL; Müller, Susanne S; Orr, Maria C M MC; Ratcliffe, Marianne J MJ; Walker, Jill J

Publication Date: 2014

Variant appearance in text: ERBB2: E61*

PubMed Link: 24956168

Variant Present in the following documents:

• Main text
• pone.0100566.pdf

View BVdb publication page